Rapid Dose Therapeutics Corp. (CSE: DOSE) announced on October 21, 2026, that it has shipped a complete QuickStrip™ production line to Callan JMB Inc. (NASDAQ: CJMB) for planned installation at its current Good Manufacturing Practice (cGMP) facility in Texas. The shipment advances a preliminary collaboration agreement first outlined in a Callan JMB announcement dated November 13, 2025. The initiative is intended to support potential U.S.-based production of fast-dissolving oral thin films, subject to definitive agreements and applicable regulatory requirements, a development investors in both companies may be watching closely.

Key Points

  • Rapid Dose Therapeutics Corp. (CSE: DOSE, OTCQB: RDTCF) — Canadian oral thin-film drug delivery biotechnology company
  • A complete QuickStrip™ production line has been shipped to Callan JMB's cGMP facility in Texas for planned installation
  • The shipment does not constitute commencement of manufacturing operations; definitive agreements and equipment qualification remain outstanding
  • Investors may monitor progress on negotiation of operational arrangements and equipment installation timelines

QuickStrip™ Technology and the Texas Facility Partnership

The proposed collaboration combines RDT's proprietary QuickStrip™ oral thin-film drug delivery platform with Callan JMB's cGMP warehousing, licensing, certification, and pharmaceutical distribution capabilities. QuickStrip™ strips dissolve rapidly in the mouth, delivering active ingredients into the bloodstream quickly. The production line shipped to Texas is designed to manufacture these films for potential applications across pharmaceutical and consumer health markets. The company states the collaboration is intended to support future U.S.-based production, pending contractual, technical, and regulatory requirements being satisfied.

Strategic Context: U.S. Market Access and Trade Policy Considerations

CEO Mark Upsdell noted in the announcement that evolving trade policies and tariffs are adding complexity to cross-border operations, positioning the Texas initiative as part of a broader strategy to strengthen RDT's U.S. market presence. The release states the shipment represents "an important step in bringing our manufacturing technology closer to the U.S. market." The disclosure suggests RDT views domestic U.S. manufacturing capacity as strategically significant given the current trade environment, though no specific financial projections or revenue guidance related to this initiative were disclosed in the announcement.

Oral Thin-Film Market Growth Cited as Industry Backdrop

RDT referenced third-party research from Straits Research, published August 24, 2026, projecting that the global oral thin films market could reach US$7.95 billion by 2034, reflecting rising demand for alternative pharmaceutical dosage formats. The company positions its planned U.S. manufacturing initiative against this industry growth backdrop. However, the announcement emphasises that production at the Texas facility remains subject to completion of definitive operational agreements, equipment qualification, and applicable regulatory approvals — none of which have been finalised at this stage.